Skip to main content
. 2019 Jul 13;11(7):981. doi: 10.3390/cancers11070981

Figure 2.

Figure 2

Kaplan-Meyer curve for OS in the overall population (OS pop) of patients treated with either FFN or GemNab. The median Overall Survival (mOS) in the overall population was 96 weeks in the FFN group and 62.6 weeks in the GemNab group (p = 0.026, 95% CI 0.14–0.88; HR = 0.35).